LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: Linking compound levels to cellular potency

Journal of Microbiological Methods

Volumn 94, Issue 2, 2013, Pages 152-158

  Bhat, Jyothi ^a   Narayan, Ashwini ^a   Venkatraman, Janani ^a   Chatterji, Monalisa ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anti infective agents; Antibiotic accumulation; Antimicrobial susceptibility; Antimycobacterial agents; Permeability

Indexed keywords

DIHYDROFOLATE REDUCTASE; ISONIAZID; RIFAMPICIN; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERIUM MUTANT; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DHFR GENE; DRUG POTENCY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; WILD TYPE;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC ACCUMULATION; ANTIMICROBIAL SUSCEPTIBILITY; ANTIMYCOBACTERIAL AGENTS; PERMEABILITY;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FOLIC ACID ANTAGONISTS; MASS SPECTROMETRY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 84880434138     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2013.05.010     Document Type: Article

References (32)

1. Ahmad S.I., Kirk S.H., Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu. Rev. Microbiol. 1998, 52:591-625.
2. Appleman J.R., Prendergast N., Delcamp T.J., Freisheim J.H., Blakley R.L. Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. J. Biol. Chem. 1988, 263:10304-10313.
3. Burchall J.J., Hitchings G.H. Inhibitor binding analysis of dihydrofolate reductases from various species. Mol. Pharmacol. 1965, 1:126-136.
4. Cai H., Rose K., Liang L.H., Dunham S., Stover C. Development of a liquid chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas aeruginosa. Anal. Biochem. 2009, 385:321-325.
5. Dhople A.M. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int. J. Antimicrob. Agents 1999, 12:319-323.
6. Dhople A.M. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J. Antimicrob. Chemother. 2000, 47:93-96.
7. Dosso M., Ouattara L., Cherif A.M., Bouzid S.A., Haller L., Fernex M. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis. Chemotherapy 2001, 47:123-127.
8. 2155: is there a clue for the unique transformability of the strain?. Microbiology 2005, 151:2075-2086.
9. Gerum A.B., Ulmer J.E., Jacobus D.P., Jensen N.P., Sherman D.R., Sibley C.H. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob. Agents Chemother. 2002, 46:3362-3369.
10. Gorlick R., Bertino J.R. Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors 1999, 37-57. Humana Press Inc., Totowa, New Jersey. A.L. Jackman (Ed.).
11. Hawser S., Lociuro S., Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 2006, 71:941-948.
12. Huennekens F.M. In search of dihydrofolate reductase. Protein Sci. 1996, 5:1201-1208.
13. Kielhofner M.A. Trimethoprim-sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex. Heart Inst. J. 1990, 17:86-93.
14. Kumar A., Zhang M., Zhu L., Liao R.P., Mutai C., Hafsat S., Sherman D.R., Wang M.W. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity 2012.
15. Li X.Z., Livermore D.M., Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 1994, 38:1732-1741.
16. Li R., Sirawaraporn R., Chitnumsub P., Sirawaraporn W., Wooden J., Athappilly F., Turley S., Hol W.G. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 2000, 295:307-323.
17. Locher H.H., Schlunegger H., Hartman P.G., Angehrn P., Then R.L. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob. Agents Chemother. 1996, 40:1376-1381.
18. Moreau N., Lacroix P., Fournel L. Antibiotic uptake by bacteria as measured by partition in polymer aqueous phase systems. Anal. Biochem. 1984, 141:94-100.
19. Mortimer P.G.S., Piddock L.J.V. A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J. Antimicrob. Chemother. 1991, 28:639-653.
20. Olliaro P. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Ther. 2000, 89:207-219.
21. Piddock L.J.V., Johnson M.M. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2002, 46:813-820.
22. Piddock L.J.V., Ricci V. Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv. J. Antimicrob. Chemother. 2001, 48:787-791.
23. Piddock L.J.V., Jin Y.F., Ricci V., Asuquo A.E. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 1999, 43:61-70.
24. Ricci V., Piddock L.J.V. Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 2000, 44:2361-2366.
25. Ricci V., Piddock L.J.V. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J. Antimicrob. Chemother. 2003, 52:605-609.
26. Schumacher A., Trittler R., Bohnert J.A., Kümmerer K., Pagès J.M., Kern W.V. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J. Antimicrob. Chemother. 2007, 59:1261-1264.
27. Snapper S.B., Melton R.E., Mustafa S., Kieser T., Jacobs W.R. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 1990, 4:1911-1919.
28. Suling W.J., Reynolds R.C., Barrow E.W., Wilson L.N., Piper J.R., Barrow W.W. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 1998, 42:811-815.
29. Urlaub G., Chasin L.A. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:4216-4220.
30. Wards B.J., Collins D.M. Electroporation at elevated temperatures substantially improves transformation efficiency of slow-growing mycobacteria. FEMS Microbiol. Lett. 1996, 145:101-105.
31. Williams K.J., Piddock L.J.V. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 1998, 42:597-603.
32. Williams K.J., Chung G.A.C., Piddock L.J.V. Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis. Antimicrob. Agents Chemother. 1998, 42:795-800.